2013 Fiscal Year Final Research Report
Hypoxic cytotoxin TX-402 might inhibit the expansion of cancer stem cells in ovarian cancer.
| Project/Area Number |
23592443
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Gifu University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ITO Naoki 岐阜大学, 医学部附属病院, 講師 (30184675)
FURUI Tatsurou 岐阜大学, 大学院医学系研究科, 准教授 (00313883)
TOYOKI Hiroshi 岐阜大学, 医学部附属病院, 講師 (40402169)
HAYASAKI You 岐阜大学, 大学院医学系研究科, 助教 (20566492)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | 卵巣癌 / 癌幹細胞 / 低酸素 / HIF / がん幹細胞 |
|---|
| Research Abstract |
In the solid tumor, the region away from the vasculatures are hypoxic and recent studies have revealed that hypoxia inducible factor (HIF) increases the fraction of cancer stem cells (CSCs). TX-402, developed as a hypoxic cytotoxin, inhibited the expression of HIF.We supposed that TX-402 might be a possible candidate as a molecular-targeted drug for ovarian cancer by inhibiting CSC expansion. Hypoxia induced the expression of HIF, stem cell factors, and putative CSC markers. Furthermore, TX-402 inhibited these stem cell factors and CSC markers, dose-dependently.
Next, we constructed the spheroids of ovarian cancer cell line, as a 3D hypoxia model, in which the internal hypoxic region contained CSCs. These hypoxic regions containing CSCs was disappeared by the treatment with TX-402.In conclusion, hypoxia might promote the expansion of CSCs, and TX-402 could be useful for ovarian cancer by inhibiting the hypoxia-induced CSC expansion.
|
-
-
-
[Journal Article] miR-92a Inhibits Peritoneal Dissemination of Ovarian Cancer Cells by Inhibiting Integrinα5 Expression2013
Author(s)
Ohyagi-Hara C,Sawada K, Kamiura S, Tomita Y, Isobe A, Hashimoto K, Kinose Y, Mabuchi S, Hisamatsu T, Takahashi T, Kumasawa K, Nagata S, Morishige KI, Lengyel E, Kurachi H,Kimura T
-
Journal Title
Am J Pathol
Volume: 182 (5)
Pages: 1876-1889
DOI
Peer Reviewed
-
-
-
-
-
[Journal Article] Chemotherapy for endometrial carcinoma (GOGO-EM1 study): TEC (paclitaxel, epirubicin, and carboplatin) is an effective remission-induction and adjuvant therapy2011
Author(s)
Egawa-Takata T, Ueda Y, Kuragaki C, Miyake T, Miyatake T, Fujita M, Yoshino K, Nakashima R, Okazawa M, Tsutsui T, Morishige KI, Kimura T, Yamasaki M, Nishizaki T, Nagamatsu M, Ito K, Asada M, Ogita K, Wakimoto A, Yamamoto T, Nishio Y, Enomoto T
-
Journal Title
Cancer Chemother Pharmacol
Volume: 68(6)
Pages: 1603-1610
DOI
Peer Reviewed
-
-
-
-
-
-
